No intent to proceed with alloHCT using donor sources not specified in this protocol, including human leukocyte antigen (HLA)-mismatched related or unrelated donors (< / HLA related matched or < / HLA unrelated matched) or umbilical cord blood unit(s).
Availability of appropriate HLA partially-matched and restricted tabelecleucel cell product
The HLA-matched donor must be medically fit to donate and willing to donate bone marrow.
Suitably HLA-matched related or unrelated donors
Any identified and available / HLA-matched related donor or / HLA-matched unrelated donor.
Available mismatched related (mMRD) or mismatched unrelated (mMUD) donor, HLA matched / or /
HLA-matched related or unrelated donor available
Recipient of / or / (human leukocyte antigen [HLA]-A, -B, -C, -DRB, -DQB) matched bone marrow allogeneic hematopoietic stem cell transplantation (HSCT) OR /, /, and / (HLA-A, -B, -DR) matched cord blood allogeneic HSCT
Availability of at least one -/ human leukocyte antigen (HLA)-matched related (excluding an identical twin) or unrelated donor, or an HLA-haploidentical related donor
The patient must have an available sibling or matched unrelated donor with at least a / human leukocyte antigen (HLA) match
Patient with a HLA-matched (HLA-A, B, C, and DR beta  [DRB] molecularly matched) unrelated donor or related donor capable of donating PBSC
HLA-matched related donors >=  years and capable and willing to donate PBSC (Arms A and B)
DONOR: HLA-matched sibling bone marrow in combination with HLA-matched sibling umbilical cord blood if the HLA-matched sibling umbilical cord blood was collected and stored; the HLA-matched sibling bone marrow and cord blood would be matched for HLA-A, B, C, DRB, and DQB
TREATMENT WITH SJCAR: CD+ ALL with any of the following:\r\n* Primary refractory disease despite at least  cycles of an intensive chemotherapy regimen designed to induce remission\r\n* Refractory disease despite salvage therapy\r\n* nd or greater relapse\r\n* Any relapse after allogeneic hematopoietic cell transplantation  \r\n* st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT for any of the following reasons:\r\n* Patients that do not have an available allogeneic donor (defined as at least a / human leukocyte antigen (HLA)-matched related/unrelated \r\ndonor, / HLA-matched umbilical cord donor, or / HLA-matched haploidentical donor)\r\n* Patients with refractory leukemia, for which allogeneic transplant is known to be less effective in the B-ALL population, and\r\n* Patients who are unable to receive myeloablative total body irradiation (TBI), which is included in standard transplant regimens for patients with B-ALL. \r\n**ALL must be confirmed to be CD+ within  months prior to enrollment for treatment
DONOR: Arm B: The recipient must have a related donor genotypically HLA-A, B, C and DRB loci haploidentical to the recipient; no HLA matched sibling or matched unrelated donor is available; DSA is allowed with desensitization done if recommended by donor selection committee (DSC) per City of Hope (COH) standard operating procedures (SOP)
Lack of a human leukocyte antigen (HLA) matched donor or need to proceed fast to transplantation when a patient does not have an immediately available matched unrelated donor (typed by high-resolution in the registry);
Patient must have planned to receive either a myeloablative or reduced-intensity conditioning regimen and have an unrelated donor who is HLA matched or single-allele mismatched
Patient in CR or has a bone marrow failure disorder or non-malignant hematologic or immune disorder: Does NOT have a sibling donor or / HLA matched unrelated donor available OR treating clinician considers haploidentical transplant preferable (despite sibling donor availability or / HLA matched donor availability) due to patients clinical status
Patient with hematologic malignancy not in CR: Does NOT have a / (or better) HLA matched related or unrelated donor available OR treating clinician considers haploidentical transplant preferable (despite sibling donor availability or / or better HLA matched donor availability) due to patients clinical status
Available related donor who is CMV+ and HLA-haploidentical or better but not fully HLA-matched
Availability of an  of  (HLA-A, B, C and DRB) HLA matched sibling or matched unrelated donor
Use of mobilized peripheral blood stem cells from fully human leukocyte antigen (HLA)-matched related or unrelated donor as a graft source
Recipients must have received an human leukocyte antigen (HLA)-identical sibling allogeneic hematopoietic stem cell transplant, or an /-matched (HLA-A, B, C, DR) other-than-sibling related donors, or a /-matched (HLA-A, B, C, DR) unrelated donor (URD) allo-hematopoietic stem cell transplantation (HSCT) for an eligible CD+ lymphoma
Must have no / or / HLA-matched sibling donor - patients >=  and =<  years of age may be eligible if they have a co-morbidity score =< 
Lack of a human leukocyte antigen (HLA) matched related donor, lack of an immediately available / HLA matched unrelated donor
Persons with a HLA matched sibling donor
Matched related or unrelated (/ matched at human leukocyte antigen [HLA]-A, -B, -C, -DRB) donor according to institutional standards
DONOR:\r\n* PART : Donor must be a / or / human leukocyte antigen (HLA)-matched sibling willing to donate PBSC for transplant\r\n* PART : Donor must be a / or / HLA-matched sibling or >= / HLA haploidentical donor willing to donate PBSC for transplant; haploidentical donors will be allowed to participate upon investigator decision and based on the data reached from / or / HLA matched transplant done during Part  of the study
HLA-matched stem cell donor, either related (/ or / loci matched) or unrelated (/ or / loci matched) \r\n* Note: unrelated donors should be matched at HLA-A, -B, -C, and -DRB loci; however, a single locus mismatch will be acceptable in the event a more closely matched donor is not available
Patients with hematologic diseases who have undergone T-cell depleted reduced intensity/non-ablative allogeneic transplantation, using a -/ HLA-matched related or unrelated donor or -/ HLA-matched related donor; this may include patients with a mixed chimeric state or disease persistence or at high risk of relapse
HLA -/ MATCHED RELATED DONOR
/ HLA MATCHED UNRELATED DONORS
No HLA matched sibling or matched unrelated donor is available
HLA-matched or partially matched (/ or /) related or unrelated donor is available to donate
Donor criteria: availability of a donor either an human leukocyte antigen (HLA) matched sibling donor (MSD) or a haploidentical (-/ HLA matched); alternatively a / HLA matched unrelated donor (MUD) by high resolution typing is immediately available
DONOR: HLA-matched or single allele mismatched sibling of enrolled transplant patient
No suitable human leukocyte antigen (HLA) matched sibling donor is available and the patient has one or more potentially suitable HLA matched unrelated donor(s) in the National Marrow Donor Registry or other available registry\r\n* The evaluation of donors shall be in accordance with existing National Marrow Donor Program (NMDP) Standard Policies and Procedures\r\n* HLA-matched donors are defined by allele matching at HLA-A, -B, -C, and DRB (/)
DONOR:  of  HLA-matched or  allele mismatched ( of ) unrelated donor
Inadequate >=  out of  human leukocyte antigen (HLA) loci-matched related donor or HLA-matched unrelated donor
Available familial haploidentical ( to  out of  HLA loci-matched) donor
Patients who do not have human leukocyte antigen (HLA)-matched (defined as matched in HLA A, B, C, and DRB) related or unrelated donors
HLA-matched donor able to donate
Must have a suitable donor defined as a sibling matched at / or / antigens (human leukocyte antigen [HLA]-A, B, and DRB) or an unrelated volunteer matched at / or / HLA alleles (HLA-A, B, C, and DRB)
Haploidentical Related Donor Selection Criteria: the recipient must have a related donor haploidentical for HLA A, B, C, and DR (i.e. matched at one locus); they may be partially matched on the other haplotype; if a matched sibling donor is available but disease status (poor disease control, recurrence after allogeneic HSCT) precludes treatment on other protocols, a haplo-identical relative is preferred as the HSC (cluster of differentiation [CD]+ cell) source
Presence of a willing adult human leukocyte antigen (HLA)-matched sibling (excluding identical twin) or HLA-matched unrelated donor meeting all the criteria for routine allo HSCT; all donors will be evaluated for eligibility and suitability per the standard of care according to the Foundation for the Accreditation of Cellular Therapy (FACT) and National Marrow Donor Program (NMDP) guidelines
RECIPIENT: / or / human leukocyte antigen (HLA)-matched related or unrelated donor or a haploidentical related donor
Patients who are deemed clinically fit for non-myeloablative transplantation and have a matched related or unrelated donor (/ human leukocyte antigen [HLA] allele matched or better using high resolution typing) eligible to provide a filgrastim (G-CSF) mobilized peripheral blood stem cell graft by institutional donor selection criteria; syngeneic donors are not permitted
Does not have a suitable human leukocyte antigen (HLA)-matched sibling donor (MSD) or volunteer HLA-matched unrelated donor (MUD) available in the necessary time for stem cell donation, or is not a candidate for MSD or MUD hematopoietic cell transplantation (HCT) due to refractory disease
Patients must have an HLA-matched donor of hematopoietic stem cells (related or unrelated)
DONOR: Patient and donor (related or unrelated) must be HLA-matched and express HLA-A*
Patients who have undergone an alemtuzumab or thymoglobulin-containing allogeneic transplant procedure from an human leukocyte antigen (HLA)-identical family donor, or an / HLA-matched unrelated donor
Must have two partially HLA-matched CBUs for part ; and one partially HLA-matched CBU for part 
HLA-matched related donor able to donate
Patients developing EBV lymphomas or lymphoproliferative disorders following an allogeneic organ transplant; in these cases, the lymphoma is usually of recipient origin; EBV-specific T-cells will be selected from the MSKCC bank expanded from an EBV-seropositive normal donor who is at least matched for )  HLA antigens and ) one restricted allele with the EBV lymphoma; if the origin of the lymphoma is unknown, T-cells partially matched with the recipient transplant will be used, since these lymphomas are usually of host origin; using this approach to donor selection, it is expected that the EBV-specific, HLA restricted cytotoxic T-cells expanded from the HLA partially-matched donor would be able to recognize and kill lymphoma cells presenting EBV antigens in the context of an appropriate HLA restricting element; priority will be given to the use of partially matched EBV specific T cells known to be restricted by an HLA allele shared by the lymphoma (or, if known, the patient)
Patients must have an HLA-identical related or HLA-matched unrelated donor
Patients for whom an human leukocyte antigen (HLA) matched sibling donor bone marrow transplant is being actively pursued will not be eligible for study until it is determined that no sibling donor is available or that a stem cell transplant is not feasible during the time the patient might be on study\r\n* No patient will be included in this study as an alternative to a clinically indicated HLA matched sibling donor stem cell transplant\r\n* If an HLA matched sibling donor is identified, but stem cell or marrow collection is not feasible (e.g., donor is in utero, is a newborn from whom cord blood was not collected, or is unable to undergo a donation procedure because of ill health), a patient may be included in the study at the discretion of the investigators
Absence of a suitable related or unrelated bone marrow donor who is molecularly matched at HLA-A, B, Cw, DRB, and DQB
Available / or / human leukocyte antigen (HLA)-matched related or unrelated donor or a haploidentical related donor
HLA-matched or single allele-mismatched donor able to donate
Cross-over from other tandem autologous-allogeneic research protocol (# or other appropriate protocol) will be allowed if the patient loses the suitable HLA-matched related or unrelated donor but has an available HLA-haploidentical donor before receiving the allogeneic transplantation and if the patient meets the eligibility criteria of the subsequent study
Patients with an available -/ HLA-A, B, DRB matched sibling donor
Recipients with unrelated donor matched at the HLA A, B, DRBI loci, or if <  years mismatched at a single HLA A or B, or DRBI locus
Partially matched related donors will be at least haploidentical (matched at >=  of  HLA A, B, DRB loci)
Patients who are ineligible for or refuse BMT from a HLA-matched, sibling donor
Matched sibling donor (HLA /), if available, or a unrelated partially HLA matched single unit based on the following priority:\r\n* First (st) priority: / matched unit, cell dose >=  x ^ nucleated cells/kg\r\n* Second (nd) priority: / matched unit, cell dose >=  x ^ nucleated cells/kg\r\n* Third (rd) priority: / matched unit, cell dose >=  x ^ nucleated cells/kg
<  years with an available -/ HLA-A, B, DRB matched sibling donor
Absence of timely and suitable fully HLA matched or one HLA locus mismatched family or unrelated donor and, at Investigator's discretion, absence of other possible therapeutic alternatives
DONOR: Donor must be related to patient and be partially (>= / antigen) HLA-matched
Patients must have resolved any serious infectious complications related to induction\r\n* NOTE: Patients with an HLA-matched donor and proceeding to transplant will be allowed up to one cycle of consolidation treatment
Must have a / or / or haploidentical related donor matched at the human leukocyte antigen (HLA)-A, B, C, DRB who was evaluated and provided the donor transplant graft
DONOR: Must be the same sibling donor from whom the recipients blood and marrow graft was collected for the original allogeneic transplant that is HLA / or / or haploidentical matched at the HLA-A, B, C, and DRB
DONOR: Must be / matched sibling donor as determined by HLA typing
Identification of a HLA-matched hematopoietic cell donor without a history of a disorder that can be transmitted by hematopoietic cells, including but not limited to inflammatory bowel disease, and without nucleotide-binding oligomerization domain containing  (NOD) mutations in the case of a HLA matched sibling
Availability of a human leukocyte antigen (HLA) matched (/) sibling donor or / matched unrelated donor; Donors with mismatch at HLA-A, HLA-B, HLA-C, and HLA-DR will be reviewed by matched unrelated donor (MUD) committee and allowed if their mismatch with the recipient does not require additional GVHD prophylaxis (other than tacrolimus and sirolimus), donors with mismatch at HLA-DQ or HLA-DPB are eligible; donor evaluation according to City of Hope (COH) standard operating procedure (SOP)
For patients in remission, there should be no readily available consenting human leukocyte antigen (HLA)-matched related donor who is either matched fully matched or mismatched at only one locus of HLA-A, -B, and DRB; patients who have active leukemia (refractory or relapsed) may be transplanted on this protocol regardless of availability of a related donor since these patients would not typically be transplanted on standard of care treatment plans
No availability of a readily available HLA-matched volunteer unrelated donor ( of  allele match at HLA-A, -B, -C and -DRB); patients with unstable disease who are in danger of significant disease progression while waiting to procure volunteer donor cells will be eligible to be treated on this protocol, even if a matched donor is available
Availability of HLA-matched or unrelated donors; related donors must be  or / antigen matched; unrelated donors must be at least / allele matched
DONOR: HLA-matched related or unrelated allogeneic donors; genotypically HLA identical twins may serve as stem cell donors; related donors must be  or / antigen matched; unrelated donors must be / allele matched
Lack of / or / human leukocyte antigen (HLA)-matched related, / HLA-matched unrelated donor, or unrelated donor not available within a time frame necessary to perform a potentially curative stem cell transplant
An human leukocyte antigen (HLA)-identical related or an HLA-matched unrelated donor (Fred Hutchinson Cancer Research Center [FHCRC] matching allowed will be Grade . to .) is available
Matched Related Donor: Related to the patient and is genotypically or phenotypically HLA-identical
Known HLA matched related donor without contraindications to donate
Patients must have two partially HLA-matched CBUs
HLA-matched donor able to donate
HLA-identical related or HLA-matched unrelated donor available
Available HLA-haploidentical donor that meets the following criteria:\r\n* Blood-related family member (sibling [full or half], offspring, parent, cousin, niece or nephew, aunt or uncle, or grandparent) \r\n* At least  years of age\r\n* HLA-haploidentical donor/recipient match by at least low-resolution typing per institutional standards\r\n* In the investigators opinion, is in general good health, and medically able to tolerate leukapheresis required for harvesting hematopoietic stem cells (HSC)\r\n* No active hepatitis\r\n* Negative for human T-lymphotropic virus (HTLV) and human immunodeficiency virus (HIV)\r\n* Not pregnant\r\n* NOTE: The HLA-matched sibling and HLA-matched unrelated donor cohorts are closed to enrollment
HLA-matched related or / allele matched (HLA-A, -B, -C, -DRB) unrelated donor available. This exclusion does not apply to HIV-positive subjects who have a CCRdelta homozygous donor.
Patients must have matched related or matched unrelated donor source OR CB unit(s) available for the primary transplant which is/are matched with the patient at , , or / human leukocyte antigen (HLA) class I (serological) and II (molecular) antigens; the cord(s) must contain at least  x ^ total nucleated cells/Kg recipient body weight (pre-thaw)
Recipient of -/ human leukocyte antigen (HLA)-matched (HLA-A, -B, -C, -DRB) allogeneic hematopoietic stem cell transplantation or a -/ HLA-matched umbilical cord blood unit(s)
Subjects should have a potential -/ HLA-matched related haploidentical donor that will be evaluated for eligibility to provide DLI
Patient with a human leukocyte antigen (HLA)-identical (HLA-A, B, C, and ribonucleic acid [RNA] binding motif protein  [DRB] molecularly matched) unrelated donor or related donor capable of donating PBSC
DONOR: HLA-matched related donors >=  years and capable and willing to donate PBSC
Suitable, / HLA matched related sibling donor available
DONORS: Matched related or unrelated donor stem cell transplant (SCT) matched at human leukocyte antigen (HLA) A- B, C, and DRB by molecular methods;  of  matched donor acceptable for related donors
HLA-Matched Related and Unrelated Donors: Patients who have an HLA-matched related or unrelated donor are eligible for entry on this protocol; this will include a healthy donor who is genotypically matched at all A, B, C, DRB and DQB loci, as tested by deoxyribonucleic acid (DNA) analysis
DONOR: Human leukocyte antigen (HLA) compatible related or unrelated donor (i.e. a fully matched unmanipulated grafts or - HLA allele disparate donor for CD selected grafts)
Patients must have a histocompatible stem cell donor; a human leukocyte antigen (HLA)-identical related donor or a / matched unrelated donor
DONOR: Donors must be an HLA matched sibling
DONOR: Donors must be HLA-matched or one antigen or allele mismatched
DONOR: Donors must be HLA-matched or one antigen or allele mismatched
MATCHED RELATED DONOR: Human leukocyte antigen (HLA)-matched related donor, excluding identical twins; donors must be matched at least  loci out of  at the allele or antigen level excluding antigen DRB mismatch
DONOR: Patients must have a healthy human leukocyte antigen (HLA) matched or mismatched related or unrelated donor who is willing to receive filgrastim (G-CSF) injections and undergo apheresis for peripheral blood stem cell (PBSC) collection, or undergo a marrow harvesting procedure
HLA-matched related and unrelated donors: \r\n* Patients who have an HLA-matched related or unrelated donor are eligible for entry on this protocol; this will include a healthy donor who is genotypically matched at all A, B, C, DRB and DQB loci, as tested by deoxyribonucleic acid (DNA) analysis
Patients must have a / HLA-matched related donor who is evaluated and deemed able to provide peripheral blood stem cells (PBSCs) and/or marrow by the transplant team
DONOR: Donor must be / HLA matched, and related to the patient
Patients with available HLA-matched related donors
No available suitably HLA- matched unrelated donor
Availability of appropriate, willing, HLA-matched related marrow donor
Patients who have suitable human leukocyte antigen (HLA)-matched related or unrelated donors willing to receive filgrastim (G-CSF), undergo leukapheresis to collect peripheral blood mononuclear cell (PBMC), and to donate stem cells
Must have an HLA genotypically or phenotypically identical related donor or, at a minimum, a high likelihood of identifying an HLA-matched unrelated donor; the determination of availability of a suitable unrelated donor may be based on a World-Book search
Cross-over to other tandem autologous-allogeneic research protocol (#) will be allowed if the patient loses the suitable HLA-matched related or unrelated donor but has an available HLA-haploidentical donor before receiving the allogeneic transplantation and if the patient meets the eligibility criteria of the subsequent study
Patients eligible for the study must have a human leukocyte antigen (HLA)-identical sibling or HLA-matched unrelated bone marrow donor available and willing to donate
For Pre-allo Part A (before stem cell transplant): Availability of an HLA matched related or unrelated donor
Lack of  / HLA matched related or / HLA A, B, C, DR matched unrelated donor; or unrelated donor not available within appropriate timeframe, as determined by the transplant physician.
HLA-matched related donor able to donate.
DONOR: donor must be related to patient and be partially (>= / antigen) HLA-matched
Patients must have one of the following donor types identified who are willing to donate peripheral blood:\r\n* Related donor, / human leukocyte antigen (HLA)-matched for HLA-A, -B, C and DR matched or\r\n* Matched unrelated donor (MUD), / HLA-matched for HLA A, B, C and DRB using allele level typing
Patients must have one or two partially HLA-matched CBUs
HLA-matched donor able to donate
Patients must have an available / human leukocyte antigen (HLA)-A, -B, -C, and -DRB matched-related or unrelated donor allogeneic hematopoietic peripheral blood stem cell graft
Availability of appropriate partially HLA-matched and restricted tabelecleucel cell product
Donor must be a / HLA-matched sibling willing to donate PBSC for transplant.
Recipient must have a / HLA-matched sibling willing to donate PBSC for transplant.
Subjects with who have undergone a non-myeloablative allogeneic transplant, using a -/ HLA matched related donor
DONOR: Sibling who is / HLA-matched with recipient
Must have an human leukocyte antigen (HLA)-matched sibling, HLA-matched unrelated donor, or a related haploidentical donor:\r\n* Available HLA-matched sibling or unrelated donor must meet the following criteria:\r\n** At least  years of age\r\n** HLA donor/recipient match based on at least low-resolution typing per institutional standards (syngeneic donors [identical twins] are excluded)\r\n** In the investigators opinion, is in general good health, and medically able to tolerate leukapheresis required for harvesting stem cells\r\n** No active hepatitis\r\n** Negative for human T-cell lymphotropic virus (HTLV) and human immunodeficiency virus (HIV)\r\n** Not pregnant OR\r\n* Available haploidentical donor must meet the following criteria:\r\n** Blood-related family member (sibling [full or half], offspring, parent, cousin, niece or nephew, aunt or uncle, or grandparent)\r\n** At least  years of age\r\n** HLA-haploidentical donor/recipient match by at least low-resolution typing per institutional standards\r\n** In the investigators opinion, is in general good health, and medically able to tolerate leukapheresis required for harvesting stem cells\r\n** No active hepatitis\r\n** Negative for HTLV and HIV\r\n** Not pregnant
Plan to receive an allogenic transplant from a -/ single or dual umbilical cord blood graft, or a -/ human leukocyte antigen (HLA)-matched sibling or unrelated donor (high resolution HLA-A, B, C, DRB)
Eligible patients will have one of the following sources of donor stem cells:\r\n* Human leukocyte antigen (HLA) matched family member\r\n* Partially matched family member (mismatched for a single HLA locus at A, B, C or DR)\r\n* Fully HLA matched or partially mismatched unrelated marrow or peripheral blood stem cells (per institutional donor selection standards)\r\n* HLA matched or partially mismatched (at least / match at A, B, DR) cord blood
Patient has a suitable and willing HLA-/ matched or / mismatched (at one allele) unrelated donor identified
Eligible participants will only be transplanted for standard clinical indications, which include hematologic malignancies such as acute leukemia, high risk lymphoma, and multiple myeloma; much less commonly there are non-malignant indications for transplants; these include aplastic anemia and severe hemoglobinopathies; no patients will be transplanted for the primary purpose of HIV eradication; patients will undergo one of the following types of transplant:\r\n* Myeloablative, human leukocyte antigen (HLA) matched or partially HLA-mismatched (haploidentical), alloHSCT that includes high-dose post-transplantation cyclophosphamide (Cy)\r\n* Nonmyeloablative, HLA matched or partially HLA-mismatched, alloHSCT that includes high-dose post-transplantation Cy
Patients must be undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) for hematologic malignancies from matched related or matched unrelated donors with / (A, B, C, DRB ) high resolution human leukocyte antigen (HLA) donor allele matching
DONOR: Must be the same sibling donor from whom the recipients blood and marrow graft was collected for the original allogeneic transplant that is human leukocyte antigen (HLA) / or / matched at the HLA-A, B,C, DRB
Availability of a suitable / HLA-A, -B, -C, and -DRB-matched unrelated mPB donor;
Human leukocyte antigen (HLA) identical sibling donor, HLA matched unrelated donor, or donor mismatched at  HLA allele or antigen
Recipients of -/ HLA-matched donor; post-HSCT period within day + to day +
Patients must have an available / HLA-A, -B, -C, and -DRB matched-related or unrelated donor allogeneic hematopoietic peripheral blood stem cell graft
Human leukocyte antigen (HLA) matched / (A, B, C, DRB) related or unrelated donor
Planned recipient of a first kidney allograft from an HLA-matched, living related donor
Availability of a suitable HLA-matched sibling or unrelated donor in a donor search
HLA-matched, related or -or / allele matched (HLA-A,-B,-Cw,-DRBl) unrelated donor able to donate.
For patients at high risk for developing aGVHD only: Recipients of myeloablative or reduced intensity allogeneic transplants using either bone marrow or peripheral blood stem cells from HLA-matched or HLA-mismatched related or unrelated donors (protocols , , ) who have not yet been placed on any therapy for acute GVHD.